Clinical Trials Logo

Filter by:
NCT ID: NCT02958865 Completed - Ulcerative Colitis Clinical Trials

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Start date: February 3, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

NCT ID: NCT02956226 Completed - Autistic Disorder Clinical Trials

Cannabinoids for Behavioral Problems in Children With ASD

CBA
Start date: January 2017
Phase: Phase 2
Study type: Interventional

This study aims to assess the safety, tolerability and efficacy of cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel] for behavioral problems in children and youth with ASD.

NCT ID: NCT02955303 Completed - Healthy Adults Clinical Trials

The Feasibility of TECH: Tablet Enhancement of Cognition and Health for Healthy Adults

Start date: November 2016
Phase: N/A
Study type: Interventional

This study assess the feasibility of novel cognitive intervention utilizing tablet apps (TECH protocol: Tablet Enhancement of Cognition and Health) in terms of relevance, adherence, suitable challenges, training time etc. for healthy older adults. Older adults with normal cognition will be randomly allocated to the TECH protocol (experimental group) or the control group (no treatment). Assessments will be administered pre and post the 6-week TECH protocol by assessors blind to group allocation.

NCT ID: NCT02955277 Completed - Clinical trials for Mild Cognitive Impairment

The Effectiveness of TECH: Tablet Enhancement of Cognition and Health

TECH
Start date: January 4, 2017
Phase: N/A
Study type: Interventional

This study assess the effectiveness of novel cognitive intervention utilizing tablet apps (TECH protocol: Tablet Enhancement of Cognition and Health) to improve cognitive abilities, daily function and health-related quality of life of older adults with MCI. Older adults with MCI will be randomly allocated to the TECH protocol (experimental group) or standard care (control group). Assessments will be administered pre and post the 6-week TECH protocol and at 6-month follow-up by assessors blind to group allocation.

NCT ID: NCT02953002 Completed - Sepsis Clinical Trials

The Correlation Between The New Sepsis Scores - SOFA, Quick SOFA and Calibrated Automated Thrombogram Values

Start date: January 17, 2017
Phase:
Study type: Observational

In total 200 subjects with diagnosis of sepsis, are planned for inclusion in this trial. After signing an informed consent a blood sample will be obtained from each participant. The investigators will measure the thrombin generation in plasma assessed by the calibrated automated thrombogram (CAT). Sequential Organ Failure Assessment score SOFA will be calculated. The relation between SOFA score and thrombin measurements will be determined.

NCT ID: NCT02952534 Completed - Clinical trials for Metastatic Castration Resistant Prostate Cancer

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

TRITON2
Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

NCT ID: NCT02951429 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension

Start date: December 31, 2016
Phase: Phase 2
Study type: Interventional

This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.

NCT ID: NCT02950051 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

GAIA
Start date: December 13, 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by combinations of targeted drugs (Venetoclax, Ibrutinib) with anti-CD20-antibodies (Rituximab, Obinutuzumab), which may induce extremely long lasting remissions.

NCT ID: NCT02945748 Completed - Clinical trials for Hemodynamic Instability

Uninvasive Cardiac Output Monitoring (USCOM) in Critically Ill Children: Validation and Prediction of Hemodynamic Instability

Start date: July 2016
Phase:
Study type: Observational

Hemodynamically unstable ventilated PICU & PCICU patients, which a decision for commencement in inotropic therapy or fluid bolus has been made, will be recruited. Hemodynamic measurements will be carried out before and after therapy have been made, including customary hemodynamic parameters, echocardiography and USCOM studies. All parameters will be analyzed for fluid responsiveness or inotropic therapy prediction. Trend in USCOM parameters will be compared to echocardiography CO parameters.

NCT ID: NCT02945735 Completed - Depressive Disorder Clinical Trials

Gaze Contingent Feedback in Major Depressive Disorder (MDD)

Start date: November 6, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of Major Depressive Disorder (MDD)